Potential therapeutic targets for the prevention of diabetic nephropathy: Glycyrrhetinic acid

doi:10.4239/wjd.v14.i12.1717

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 14, Issue 12

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (1477)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-1) series.

Item

Count

PDF

WORD

HTML

837

Figures (1-1)

Sum=999

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

123

Download

104

Sum=227

Publishing Process of This Article

Item

Count

Browse

Download

Sum=166

Dec 15, 2023 (publication date) through May 15, 2024

Times Cited of This Article

Times Cited (2)

Journal Information of This Article

Publication Name

World Journal of Diabetes

ISSN

1948-9358

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Editorial

World J Diabetes. Dec 15, 2023; 14(12): 1717-1720
Published online Dec 15, 2023. doi: 10.4239/wjd.v14.i12.1717

Open in New Tab Full Size Figure Download Figure

Figure 1 Summary of the beneficial effects of glycyrrhetinic acid family members. The left panel summarizes the well-known beneficial effects based on several reviews cited in this editorial publication[8-10]. The right panel of this figure as a small part of total research on provides the limited publications that showed the certain protective effects on metabolic syndrome, hyperglycemia, and potential diabetic complications. GA: Glycyrrhetinic acid.

Citation: Cai L, Horowitz M, Islam MS. Potential therapeutic targets for the prevention of diabetic nephropathy: Glycyrrhetinic acid. World J Diabetes 2023; 14(12): 1717-1720
URL: https://www.wjgnet.com/1948-9358/full/v14/i12/1717.htm
DOI: https://dx.doi.org/10.4239/wjd.v14.i12.1717